- Home
- RBNE vs GMAB Comparison
RBNE vs GMAB Comparison
Compare RBNE & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBNE
- GMAB
- Stock Information
- Founded
- RBNE 2024
- GMAB 1999
- Country
- RBNE Cyprus
- GMAB Denmark
- Employees
- RBNE N/A
- GMAB N/A
- Industry
- RBNE Marine Transportation
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- RBNE Consumer Discretionary
- GMAB Health Care
- Exchange
- RBNE Nasdaq
- GMAB Nasdaq
- Market Cap
- RBNE 6.8M
- GMAB 12.8B
- IPO Year
- RBNE N/A
- GMAB N/A
- Fundamental
- Price
- RBNE $2.74
- GMAB $20.95
- Analyst Decision
- RBNE
- GMAB Buy
- Analyst Count
- RBNE 0
- GMAB 9
- Target Price
- RBNE N/A
- GMAB $39.17
- AVG Volume (30 Days)
- RBNE 17.4K
- GMAB 1.5M
- Earning Date
- RBNE 06-06-2025
- GMAB 05-08-2025
- Dividend Yield
- RBNE N/A
- GMAB N/A
- EPS Growth
- RBNE N/A
- GMAB 276.13
- EPS
- RBNE N/A
- GMAB 18.36
- Revenue
- RBNE N/A
- GMAB $3,230,902,140.00
- Revenue This Year
- RBNE N/A
- GMAB $17.69
- Revenue Next Year
- RBNE N/A
- GMAB $14.81
- P/E Ratio
- RBNE N/A
- GMAB $11.30
- Revenue Growth
- RBNE N/A
- GMAB 25.21
- 52 Week Low
- RBNE $2.38
- GMAB $17.24
- 52 Week High
- RBNE $6.53
- GMAB $28.96
- Technical
- Relative Strength Index (RSI)
- RBNE N/A
- GMAB 55.72
- Support Level
- RBNE N/A
- GMAB $20.73
- Resistance Level
- RBNE N/A
- GMAB $21.42
- Average True Range (ATR)
- RBNE 0.00
- GMAB 0.45
- MACD
- RBNE 0.00
- GMAB 0.11
- Stochastic Oscillator
- RBNE 0.00
- GMAB 81.62
About RBNE Robin Energy Ltd. Common Stock
Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.